Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients

Summary

Inflammation is central to the pathogenesis and progression of atherosclerosis and thrombosis, the underlying cause of major cardiovascular disease. Platelets, in addition to their role in haemostasis, play a key role in both thrombus formation and inflammation following vascular injury, especially atherosclerotic lesions. An increasing body of evidence suggests that inhibition of platelet function can modulate inflammatory markers, particularly those associated with activated platelets, such as CD40 ligand, P-selectin, and C-reactive protein. The currently available antiplatelet agents aspirin, clopidogrel, prasugrel, abciximab, and eptifibatide have shown varying effects on inflammatory markers. These effects seem to be mostly indirect, i.e. mediated primarily through reduced platelet activation that results in reduced inflammatory marker expression. However, there is some evidence that suggests direct effects (i.e. those independent of platelets) may also play a role in modulating inflammatory markers. Evidence linking inflammation and thrombosis supports the hypothesis that agents with both anti-inflammatory and antiplatelet effects may reduce vascular inflammation and limit acute and long-term thrombotic events. An assessment of the involvement of inflammatory mediators in atherosclerosis may provide further insight into important predictive markers of cardiovascular outcomes that may also serve as potential therapeutic targets. This review examines the evidence for and potential clinical relevance of the effects of antiplatelet therapy on inflammatory markers.

Keywords

Antiplatelet therapy - thrombosis - inflammation - platelets

• References

• 1 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 2 van der Wal AC, Becker AE. Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability. Cardiovasc Res 1999; 41: 334-344.
• 3 Gawaz M. et al. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
• 4 Rex S. et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 2009; 102: 97-110.
• 5 Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-486.
• 6 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 7 Libby P. et al. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
• 8 Chamorro A. Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 2004; 17 (Suppl. 03) 1-5.
• 9 Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-1720.
• 10 Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
• 11 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 08: 1227-1234.
• 12 Mach F. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936.
• 13 Schober A. et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-1529.
• 14 Frenette PS. et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on plate -lets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413-1422.
• 15 Lindmark E. et al. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-2328.
• 16 Hemker HC. et al. Platelet membrane involvement in blood coagulation. Blood Cells 1983; 09: 303-317.
• 17 Nagy Jr. B. et al. Binding of plasma factor XIII to thrombin-receptor activated human platelets. Thromb Haemost 2009; 102: 83-89.
• 18 Bevers EM. et al. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-436.
• 19 Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003; 07: 23-38.
• 20 Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007; 219: 187-203.
• 21 Varo N. et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-1052.
• 22 Schönbeck U. et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-2268.
• 23 Henn V. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
• 24 Aukrust P. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-620.
• 25 Schober A. et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-1529.
• 26 Noto D. et al. Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thromb Haemost 2007; 98: 1362-1367.
• 27 Ridker PM. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
• 28 Liuzzo G. et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
• 29 Liuzzo G. et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98: 2370-2376.
• 30 Licata G. et al. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost 2009; 101: 929-937.
• 31 Solheim S. et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660-664.
• 32 Nelken NA. et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-1127.
• 33 Hoogeveen RC. et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005; 183: 301-307.
• 34 Ridker PM. et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
• 35 Albert MA. et al. Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: a pro -spective analysis of the Women’s Health Study. Atherosclerosis 2008; 197: 297-302.
• 36 Kitagawa K. et al. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis 2002; 160: 305-310.
• 37 Pradhan AD. et al. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-825.
• 38 Garlichs CD. et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86: 649-655.
• 39 Zebrack JS. et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002; 89: 145-149.
• 40 Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999; 147: 213-225.
• 41 Seljeflot I. et al. Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction. J Thromb Haemost 2004; 02: 350-352.
• 42 Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation 2003; 108: III22-III27.
• 43 Viles-Gonzalez JF. et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. Eur Heart J 2005; 26: 1557-1561.
• 44 Judge HM. et al. The active metabolite of prasugrel effectively blocks the platelet P2Y₁₂ receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 2008; 19: 125-133.
• 45 Frelinger AL. 3rd, et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007; 98: 192-200.
• 46 Storey RF. et al. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y₁₂ receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002; 88: 488-494.
• 47 Hermann A. et al. Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
• 48 Evangelista V. et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost 2005; 94: 568-577.
• 49 Ayral Y. et al. Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model. Cardiovasc Revasc Med 2007; 08: 183-188.
• 50 Egan KM. et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque de -stabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-342.
• 51 Herbert JM. et al. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-2286.
• 52 Molero L. et al. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol 2005; 146: 419-424.
• 53 Patrono C. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
• 54 Weber C. et al. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91: 1914-1917.
• 55 Ridker PM. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
• 56 Ikonomidis I. et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-798.
• 57 Chen YG. et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J (Engl) 2006; 119: 32-36.
• 58 Solheim S. et al. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 2003; 92: 843-845.
• 59 Li N. et al. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170.
• 60 CAPRIE Steering Committee.. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
• 61 Chen ZM. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
• 62 Sabatine MS. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189.
• 63 Sabatine MS. et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. J Am Med Assoc 2005; 294: 1224-1232.
• 64 Mehta SR. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
• 65 Steinhubl SR. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
• 66 Yusuf S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 67 Klinkhardt U. et al. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002; 71: 176-185.
• 68 Klinkhardt U. et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73: 232-241.
• 69 Rao AK. et al. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006; 96: 738-743.
• 70 Azar RR. et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151: 521.e1-521.e4.
• 71 Heitzer T. et al. Clopidogrel improves systemic endothelial nitric oxide bioavail-ability in patients with coronary artery disease: evidence for antioxidant and anti-inflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26: 1648-1652.
• 72 Vavuranakis M. et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther 2006; 28: 860-871.
• 73 Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-1988.
• 74 Vivekananthan DP. et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358-360.
• 75 Quinn MJ. et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679-684.
• 76 Saw J. et al. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008; 52: 1826-1833.
• 77 Montalescot G. et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-938.
• 78 Seyfarth HJ. et al. Effect of 300– and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002; 143: 118-123.
• 79 Patti G. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-2106.
• 80 von Beckerath N. et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-2950.
• 81 Serebruany VL. et al. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006; 82: 404-410.
• 82 Braun OÖ. et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008; 100: 626-633.
• 83 Jakubowski JA. et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y₁₂ inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007; 63: 421-430.
• 84 Wiviott SD. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
• 85 Frelinger AL. 3rd, et al. The active metabolite of prasugrel inhibits adenosine di -phosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008; 06: 359-365.
• 86 Mascelli MA. et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/ IIIa receptor blockade. Circulation 1998; 97: 1680-1688.
• 87 Kereiakes DJ. Effects of GP IIb/IIIa Inhibitors on Vascular Inflammation, Coronary Microcirculation, and Platelet Function. Rev Cardiovasc Med 2006; 07 (Suppl. 04) S3-S11.
• 88 Lincoff AM. et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163-167.
• 89 Merino A. et al. Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: effect of the –174 G/C IL-6 gene polymorphism. Am J Cardiol 2004; 94: 1300-1303.
• 90 James SK. et al. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. Am Heart J 2004; 147: 267-274.
• 91 Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-1924.
• 92 Gurbel PA. et al. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006; 48: 2186-2191.
• 93 Angiolillo DJ. et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780-784.
• 94 Husted S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y₁₂ antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
• 95 Pels K. et al. Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs. Eur J Clin Invest 2009; 39: 174-182.
• 96 Salanova B. et al. Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils. J Biol Chem 2007; 282: 27960-27969.
• 97 Winning J. et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009; 20: 50-57.
• 98 Bhatt DL. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
• 99 Bhatt DL. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988.
• 100 Gawaz M. et al. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
• 101 von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
• 102 Hanriot D. et al. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost 2008; 99: 558-569.
• 103 Liuzzo G. et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98: 2370-2376.
• 104 Yaron G. et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol 2006; 134: 426-431.
• 105 Papanicolaou DA. et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
• 106 Girndt M, Kohler H. Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. Nephrol Dial Transplant 2003; 18: 1976-1979.
• 107 Hansson GK. et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
• 108 Yang L. et al. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 2005; 106: 584-592.
• 109 Carr MW. et al. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994; 91: 3652-3656.
• 110 Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-1988.